SUVENPHAR.BOSUVENPHAR.BOBSE
Loading
| Metric | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 |
|---|---|---|---|---|---|
| Revenue Growth | +39.73% | +58.95% | +138.12% | +115.57% | +77.29% |
| Gross Profit Growth | +119.33% | -4.48% | +186.53% | +101.52% | +53.32% |
| EBITDA Growth | +72.33% | +28.43% | +8.51% | +33.58% | -12.38% |
| Operating Income Growth | +136.58% | -31.45% | +183.77% | -49.98% | -74.28% |
| Net Income Growth | +77.27% | -21.29% | -19.57% | -9.89% | -55.69% |
| EPS Growth | +77.17% | -21.90% | -20.08% | -10.53% | -55.83% |
| EPS Diluted Growth | +75.54% | -25.24% | -20.08% | -9.66% | -55.42% |
| Weighted Average Shares Growth | +0.98% | +5.59% | +0.86% | +0.13% | -0.06% |
| Weighted Average Shares Diluted Growth | +0.98% | +3.96% | +0.61% | -0.11% | -0.30% |
| Dividends per Share Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| Operating Cash Flow Growth | -100.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| Free Cash Flow Growth | -100.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| Receivables Growth | -100.00% | +113.10% | +0.00% | +225.06% | +0.00% |
| Inventory Growth | -100.00% | -27.95% | +0.00% | +175.14% | +0.00% |
| Asset Growth | -100.00% | +34.50% | +0.00% | +122.25% | +0.00% |
| Book Value per Share Growth | +1.38% | -21.65% | -11.00% | +91.21% | +0.00% |
| Debt Growth | -100.00% | +329.36% | +0.00% | +1042.35% | +0.00% |
| R&D Expense Growth | -100.00% | -100.00% | +0.00% | +0.00% | +0.00% |
| SG&A Expenses Growth | +92.77% | +93.66% | +192.24% | -100.00% | -100.00% |